To analyse long-term overall survival, relapse-free survival and late toxicities in a series of 675 patients treated between 1999 and 2003, with a median follow-up of 132 months.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The cohort included low-risk patients and a selection of "favourable-intermediate" risk patients. All patients were homogeneously treated using an intraoperative dynamic planning prostate brachytherapy technique, with loose 125 iodine seeds. Hormone therapy, consisting most often of an anti-androgen alone, was given in 393 patients (58%).
The 10-year overall survival was 92% (95% confidence interval [CI]: 90-94) without a significant difference between the low and the select intermediate-risk groups (P=0.17). The 10-year relapse-free survival rate for the entire cohort was 82% (95% CI: 79-85), and was significantly higher in the low-risk group than in the intermediate one (87 vs 71%; P<0.0001). Twenty-six percent of the relapses observed in this series occurred after more than 10 years of follow-up. The 10-year cumulative incidence of grade 3-4 urinary toxicity (whatever the delay and the recovery) was 5.78%. The cumulative incidence of grades 3-4 rectal toxicity in the present series was 1.65% at 10 years. As for sexual toxicity, 61% of our patients retained an erectile capacity at 10 years (with or without oral medication), with age being a major factor.
With a median follow-up of more than 11 years, this series appears to confirm the excellent long-term results of low-dose rate prostate brachytherapy, both in terms of survival and in terms of toxicity.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2016 Jun 15 [Epub ahead of print]
J-M Cosset, T Flam, L Belin, N Thiounn, N Pierrat, D Pontvert, G Wakil, A Savignoni, L Chauveinc
Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Centre de radiothérapie Charlebourg-La-Défense, groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France. Electronic address: ., Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Fondation Saint-Jean-de-Dieu-Oudinot, 19, rue Oudinot, 75007 Paris, France., Institut Curie, 26, rue d'Ulm, 75005 Paris, France., Hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France., Institut Curie, 26, rue d'Ulm, 75005 Paris, France., Institut Curie, 26, rue d'Ulm, 75005 Paris, France., Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Charles Lemoyne Hospital, 3120, boulevard Taschereau, Greenfield Park, J4V 2H1 Montréal, QC, Canada., Institut Curie, 26, rue d'Ulm, 75005 Paris, France., Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Centre de radiothérapie Hartmann, 4, rue Kléber, 93200 Levallois-Perret, France.